Session Type
Date Time

Prevention and treatment landscape for HIV has come a long way since the first U.S. Food and Drug Administration (FDA) approved antiretroviral therapy (ART) in 1987 to numerous options presently available on the market. Given that lifelong treatment may pose several challenges to clients, including stigma, pill burden and non-adherence, it is important to provide with a variety of treatment and prevention options that would meet the needs and wants of clients. With the first long-acting regiments being approved by FDA in 2021, long-acting technologies are the exciting addition to the HIV treatment and prevention toolbox that could address some of these issues. However, there is a need to further explore opportunities and mitigate anticipated challenges they might create for the beneficiary populations and healthcare systems that they cater to. This satellite, co-organized by IAS Industry Liaison Forum and the Medicines Patent Pool, will bring together key stakeholders from ministries of health, civil society, industry, communities, funders, implementers, and researchers. The aim is to provide the audience with the current landscape of HIV prevention and treatment long-acting technologies, discuss the differentiated service delivery models that can be used to ensure these technologies reach the various communities vulnerable to HIV and do not burden the healthcare system and lastly discuss the technology transference possibilities for some of these technologies to increase their availability and affordability.

5 min
Welcome and introduction
Adeeba KAMARULZAMAN, University Malaya, Malaysia
Charles GORE, Medicines Patent Pool, Switzerland
15 min
Landscape of long-acting HIV prevention and treatment innovations
Charles FLEXNER, Johns Hopkins University, United States
15 min
Sustainable service delivery in the long-acting technology era
Nittaya PHANUPHAK, Institute of HIV Research and Innovation, Thailand
15 min
Pathways for timely and at-scale access to quality affordable long-acting HIV innovations
Cherise SCOTT, Unitaid, Switzerland
5 min
New WHO guidance: Long-acting cabotegravir for HIV prevention
Rachel BAGGALEY, World Health Organization, Switzerland
30 min
Panel discussion
Wesley KREFT, PFSCM, Netherlands
Mitchell WARREN, AVAC, United States
Anton POZNIAK, Chelsea & Westminster and LSHTM, United Kingdom
Helen MCDOWELL, ViiV Healthcare, United Kingdom
Nina RUSSELL, Bill & Melinda Gates Foundation, United States
David RIPIN, Clinton Health Access Initiative (CHAI), United States
Lillian MWOREKO, International Community of Women living with HIV Eastern Africa (ICWEA), Uganda
Kenly SIKWESE, AfroCAB, Zambia
5 min
Summary and closing
Adeeba KAMARULZAMAN, University Malaya, Malaysia
Charles GORE, Medicines Patent Pool, Switzerland